Latest News

With a price-to-earnings (or "P/E") ratio of 19x Galaxy Entertainment Group Limited ( HKG:27 ) may be sending very...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Key Insights Insiders appear to have a vested interest in Great Rich Technologies' growth, as seen by their sizeable...

JK Synapse Co., Ltd. ( KOSDAQ:060230 ) shares have had a really impressive month, gaining 33% after a shaky period...

Genscript Biotech (SEHK:1548) is back in focus after its associate Legend Biotech reported approximately US$555 million in Q4 2025 net trade sales of multiple myeloma cell therapy CARVYKTI®, underscoring meaningful commercial traction. See our latest analysis for Genscript Biotech. Legend Biotech’s CARVYKTI® sales update has arrived after a mixed year for Genscript Biotech, with the share price at HK$13.3, a year to date share price return of 3.99%, a 1 year total shareholder return of 26.19%...

Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses. This designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile. Next, we’ll examine how pemvidutide’s Breakthrough...

National HealthCare Corporation recently reached a record high level after reporting 22.67% revenue growth over the past year and declaring a US$0.64 quarterly dividend per share, underscoring its focus on returning cash to shareholders. The company’s ‘GREAT’ financial health score, combined with strong recent results and ongoing dividend payments, may be reinforcing investor confidence in its operational resilience. We’ll now examine how National HealthCare’s robust revenue growth and...

When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 15x, you may consider Tokyo...

Most readers would already be aware that Nikon's (TSE:7731) stock increased significantly by 13% over the past month...

Trend Micro (TSE:4704) has had a rough three months with its share price down 21%. However, stock prices are usually...

Capricorn Metals (ASX:CMM) has had a great run on the share market with its stock up by a significant 19% over the last...

In January 2026, Interroll announced the departure of Chief Operating Officer Ayan Demirel and Chief Technology Officer Dr. Johannes Van Der Beek, with CEO Markus Asch temporarily assuming operational leadership and industry veteran Ulrich Engenhardt joining as the new CTO. These simultaneous changes in operations and technology leadership highlight a pivotal moment for Interroll’s organisational direction, particularly around product platforms, regional capabilities and innovation...

In recent months, analysts have become more positive on The RealReal after the company reported past third-quarter results that outpaced forecasts for revenue and adjusted EBITDA. Alongside this, The RealReal’s introduction of its Athena AI system to support authentication, descriptions, and pricing underscores a push toward greater efficiency in its luxury resale operations. Next, we’ll explore how this combination of analyst confidence and Athena-driven operational enhancement shapes The...

Production update and why it matters for CGN Mining CGN Mining (SEHK:1164) has released unaudited natural uranium production figures, reporting 702.5 tU for the fourth quarter of 2025 and 2,699.0 tU for the full year. This provides investors with fresh insight into recent operating performance. See our latest analysis for CGN Mining. The production update lands after a strong run in the shares. The latest HK$4.3 price comes alongside a 32.72% year to date share price return and a very large 5...

Carrefour recently began piloting environmental labelling for around 70 items in its Tex clothing range, allowing customers to scan barcodes via the Clear Fashion app to view each garment’s environmental score based on factors like greenhouse gas emissions and biodiversity impact. This trial could help Carrefour learn which digital and in-store tools best encourage eco-conscious choices, potentially informing a wider rollout across all of its textile collections. We’ll now examine how this...

In recent days, QuidelOrtho has faced renewed scrutiny over its financial position, with analyses pointing to negative earnings, shrinking margins, a low interest coverage ratio and an Altman Z-Score of 0.2 that places the diagnostics group in the distress zone. Alongside these concerns, the company has highlighted its role in blood-supply resilience and plans to report fourth-quarter and full-year 2025 results on February 11, 2026, underscoring a contrast between operational initiatives and...

As the Asian markets navigate a landscape marked by mixed economic signals, investors are keenly observing opportunities that may arise from current market fluctuations. In this environment, identifying stocks trading at an estimated discount requires a focus on companies with strong fundamentals and resilience in the face of global uncertainties.

As global markets face volatility and economic indicators show mixed signals, the Asian market continues to present unique opportunities for investors seeking growth potential in small-cap stocks. In this environment, a good stock is often characterized by strong fundamentals, resilience to macroeconomic shifts, and the ability to capitalize on regional economic trends.

Earlier in 2026, OCBC highlighted The Hour Glass as a potential privatisation candidate, citing undemanding valuations and high ownership concentration, while analysts pointed to supportive macro conditions and equity market reforms for Singapore small and mid-caps. This combination has drawn fresh attention to The Hour Glass as a quality SMID name where investors are watching closely for possible corporate actions and long-term structural growth drivers. Next, we’ll examine how OCBC’s...

Record profit outlook puts recent share gains in focus COSCO SHIPPING Energy Transportation (SEHK:1138) is in the spotlight after projecting record profit for 2025 and signaling strong year-on-year growth for early 2026, supported by resilient oil transport demand and constrained shipping capacity. See our latest analysis for COSCO SHIPPING Energy Transportation. Investors have responded quickly to COSCO SHIPPING Energy Transportation’s outlook, with a 30 day share price return of 33.68% and...

Why Malcolm Wilson’s Appointment Matters For SATS (SGX:S58) Investors SATS (SGX:S58) has appointed Malcolm Wilson as an Independent Non Executive Director, bringing boardroom experience from global logistics groups such as Dawson Group and GXO Logistics, with a focus on technology driven transformation. See our latest analysis for SATS. At a share price of SGD3.88, SATS has shown building momentum recently, with an 11.82% 90 day share price return and a 14.67% 1 year total shareholder return...

Why Sany Heavy Equipment International Holdings (SEHK:631) is Back on Investor Radar Sany Heavy Equipment International Holdings (SEHK:631) has disclosed plans to subscribe for financial products from CICC Group, highlighting its capital allocation choices for investors watching how the company manages liquidity. See our latest analysis for Sany Heavy Equipment International Holdings. The intent to place funds into CICC Group products comes at a time when Sany Heavy Equipment International...

PTC Therapeutics (PTCT) recently issued full year 2026 product revenue guidance of US$700 million to US$800 million, excluding Evrysdi royalties and collaboration revenue. This guidance serves as a key reference point for investors tracking the stock. See our latest analysis for PTC Therapeutics. The 12.18% 3 month share price return and 62.0% 1 year total shareholder return suggest momentum has been building around PTC Therapeutics, with the new 2026 product revenue guidance adding to recent...

Donnelley Financial Solutions recently reported Q3 2025 results that surpassed earnings expectations and outlined plans to increase the share of revenue from software solutions to 60% by 2028, while attracting new investment from the RAM Smid Composite fund. This pivot toward higher-margin software and technology-enabled compliance tools marks a meaningful shift in how the company positions itself within the regulatory and financial reporting ecosystem. We will now examine how Donnelley...